- Policy
- The introduction of Moderna COVID-19 vaccine has begun
- by Kim, Jung-Ju Sep 16, 2022 05:53am
- Moderna's omicron mutation (BA.1) bivalent vaccine of 1.611 million doses will be introduced in Korea sequentially from today (15th). According to the Korea Centers for Disease Control and Prevention, 805,000 doses will arrive at Incheon International Airport on the 15th and 806,000 doses on the 17th, respectively, and will be used for winter va
- Policy
- The flu-coronavirus outbreak has been predicted
- by Kim, Jung-Ju Sep 15, 2022 05:55am
- Amid the prevailing pessimistic outlook that flu and COVID-19 will be all the rage at the same time this fall, quarantine authorities stressed that flu and COVID-19 vaccines should be vaccinated respectively. This is due to similar symptoms such as headaches and fever, which can be mistaken, and people are confused by rumors that "if getting
- Policy
- Lowest price falls to PVA
- by Lee, Tak-Sun Sep 14, 2022 05:50am
- Despite the increase from 1.5 billion won to 2 billion won based on claims, the industry "needs small and medium-sized pharmaceutical remedies." Some products fell to the lowest price under PVA this year. Most of the products of small and medium-sized pharmaceutical companies lost money. According to industries on the 12th, some products suc
- Policy
- GOV·Pharma starts work to localize 57 essential medicines
- by Lee, Jeong-Hwan Sep 13, 2022 05:52am
- The government and the pharmaceutical industry have entered the final stages of localizing the finished drug products and active pharmaceutical ingredients that are essential for national disease control and prevention as well as the treatment of emergency patients. The supply of such products and ingredients has been mainly dependent on imp
- Policy
- Paxlovid is contraindicated with other concomitant meds
- by Lee, Tak-Sun Sep 13, 2022 05:51am
- Piroxicam was excluded from the list among drugs that should not be taken with Paxlovid, an oral COVID-19 treatment. As a result, the number of combination contraindications has decreased to 16, but there are many contraindications, making it difficult for patients with chronic diseases who take drugs every day to take Piroxicam. The HIRA
- Policy
- Approval of Boryung’s new SCLC drug Zepzelca imminent
- by Lee, Hye-Kyung Sep 8, 2022 05:58am
- Boryung Pharmaceutical’s new drug for small-cell lung cancer (SCLC), 'Zepzelca inj, (lurbinectedin) is soon to be granted marketing approval in Korea. Currently, Hycamtin inj (topotecan)’ and ‘Camtobell Inj (belotecan)’ are approved for second-line use in Korea. According to industry sources on the 7th, the Ministry of Food and Dr
- Policy
- MOHW to provide premium pricing support for innovative drugs
- by Lee, Jeong-Hwan Sep 7, 2022 05:52am
- The Korean government has emphasized the need to enact subordinate statutes to give preferential treatment to new drugs manufactured by Korea Innovative Pharmaceutical Companies and promises to prepare policy support. This announcement reflects the authorities’ determination to find a way to provide preferential treatment for drug prices
- Policy
- What's patient-centered safety in the biopharmaceutical era?
- by Lee, Hye-Kyung Sep 7, 2022 05:52am
- Along with the application of the world's first CAR-T cell therapy Kymriah and Zolgensma, an alternative treatment for spinal proximal phagocytosis (SMA), the biopharmaceutical era has opened in Korea. Controversy over safety and accessibility has not yet been resolved in the process of innovative biopharmaceuticals being developed and used to t
- Policy
- Antiemetic Emend's generic benefit after 15 yrs since origin
- by Lee, Tak-Sun Sep 7, 2022 05:51am
- As the generic of Emend will be applied starting this month, the burden of drug prices for patients is expected to decrease. It is the first time in 15 years that generic for Emend capsule has been reimbursed since the original was listed. According to industries on the 5th, Acepharma's Atant 80mg and Atant 125mg have been registered as be
- Policy
- Enactment of preferential pricing sublaws slow
- by Lee, Jeong-Hwan Sep 6, 2022 05:51am
- The enactment of subordinate statutes for the so-called ‘preferential drug pricing for Korean Innovative Pharmaceutical Companies’ clause of the ‘Special Act On Fostering and Support of Pharmaceutical Industry’ is hardly picking up speed. Although the research service ordered by the Ministry of Health and Welfare and the Korea Health
